SEATTLE (AP) — The planned buyout of Trubion Pharmaceuticals Inc. by Emergent BioSolutions Inc. cleared a regulatory hurdle Wednesday, bringing the deal, potentially worth $135.5 million, closer to closing.
The Department of Justice and Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Act for the acquisition, Trubion said.
The buyout still needs approval from Trubion shareholders before Rockville, Md.-based Emergent can complete the deal.
Emergent said last month it …
Комментариев нет:
Отправить комментарий